Shorter steroid course may be just as effective for giant cell arteritis
NCT ID NCT04012905
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a shorter, lighter course of corticosteroids (28 weeks) works as well as the standard longer course (52 weeks) for giant cell arteritis, a condition that inflames blood vessels. The study aims to reduce side effects from long-term steroid use. 150 newly diagnosed patients will be randomly assigned to one of the two tapering schedules and followed for a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Corticosteroids (prednisone)
What this could lead to
If successful, this could show that a shorter course of steroids works just as well as a longer one, reducing side effects for patients with giant cell arteritis.
What could go wrong
This is a relatively small trial (150 people) and only compares two steroid tapering schedules, not a new treatment. The shorter course may lead to more relapses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Caen Normandie
RECRUITINGCaen, 14000, France
Contact